


AMENDMENTS TO THE CLAIMS

1. **(Currently Amended)** A chewing gum pharmaceutical composition comprising:

- a core comprising a first formulation, which contains an active compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acids and their amides having the general formula I

Formula I



wherein

R₁ is a -COOH group or a -CONH₂ group, and


X₁ and X₂, taken separately, each represent a hydrogen atom, a halogen atom, a straight-chain or branched C₁-C₄ alkoxy group or a trifluoromethyl group as well as their pharmaceutically acceptable salts, geometrical isomers, enantiomers, diastereomers and mixtures thereof, and which first formulation does not contain polyols having a molecular weight of less than 300 in a molar ratio between the polyol and active compound of formula I above 10, and additionally containing a gum base; and

- a coating comprising a second formulation, which contains one or more solid polyol(s) with a molecular weight of less than 3000 and is free of a compound of formula I, wherein a polyol in the second formulation contains a first polyol which is a polysaccharide and wherein the second formulation contains a second polyol selected from the group consisting of mannitol, sorbitol and xylitol in an amount sufficient to improve the palatability of the pharmaceutical composition.

2. **(Original)** A composition according to claim 1 wherein the first formulation does not contain polyols having a molecular weight of less than 950 in a molar ratio between polyol and active compound of formula I above 10, with the exception of lactose.
3. **(Original)** A composition according to claim 1 wherein the first formulation does not contain polyols having a molecular weight of less than 300 in a molar ratio between polyol and active compound of formula I above 5.
4. **(Cancelled)**
5. **(Previously presented)** A composition according to claim 1 wherein the first formulation does not contain polyols having a molecular weight of less than 950 in a molar ratio between polyol and active compound of formula I above 5, with the exception of lactose.
6. **(Previously presented)** A composition according to claim 1 wherein the first formulation does not contain polyols having a molecular weight of less than 950, with the exception of lactose.
7. **(Previously presented)** A composition according to claim 1 wherein the formulations are prepared in the form of powders, granules, solutions or suspensions.
8. **(Previously Presented)** A composition according to claim 1 wherein a polyol in the second formulation is mannitol.
9. **(Cancelled)**

10. **(Previously presented)** A composition according to claim 1 wherein at least one of the formulations further contains an alkalinizing agent.
11. **(Previously presented)** A composition according to claim 10 wherein the alkalinizing agent is sodium citrate.
12. **(Previously presented)** A composition according to claim 1 wherein the first formulation further contains one or more excipients selected from cyclodextrins, colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, flavors or colorants.
13. **(Previously presented)** A composition according to claim 1 wherein the first formulation further contains non-polyol sweetening agents such as acesulfame K, aspartame, saccharine, saccharine sodium or cyclamate.
14. **(Previously presented)** A composition according to claim 1 wherein the active compound in the first formulation is cetirizine dihydrochloride, levocetirizine dihydrochloride or efletirizine dihydrochloride.
- 15-22. **(Cancelled)**
23. **(Currently Amended)** A chewing gum pharmaceutical composition comprising:
 - a coating comprising a first formulation, which contains an active compound selected from 2-[4-(diphenylmethyl)-1-piperazinyl]-acetic acids and their amides having the general formula I

Formula I



wherein

R₁ is a -COOH group or a -CONH₂ group, and

X₁ and X₂, taken separately, each represent a hydrogen atom, a halogen atom, a straight-chain or branched C₁-C₄ alkoxy group or a trifluoromethyl group as well as their pharmaceutically acceptable salts, geometrical isomers, enantiomers, diastereomers and mixtures thereof, and which first formulation does not contain polyols having a molecular weight of less than 300 in a molar ratio between the polyol and active compound of formula I above 10; and

- a core comprising a second formulation, which contains one or more solid polyol(s) with a molecular weight of less than 3000 and is free of a compound of formula I, wherein a polyol in the second formulation contains a first polyol which is a polysaccharide, wherein the second formulation contains a second polyol selected from the group consisting of mannitol, sorbitol and xylitol in an amount sufficient to improve the palatability of the pharmaceutical composition, and additionally containing a gum base.

24. **(Previously presented)** A composition according to claim 23 wherein the first formulation does not contain polyols having a molecular weight of less than 950 in a molar ratio between polyol and active compound of formula I above 10, with the exception of lactose.

25. **(Previously presented)** A composition according to claim 23 wherein the first formulation does not contain polyols having a molecular weight of less than 300 in a molar ratio between polyol and active compound of formula I above 5.
26. **(Previously presented)** A composition according to claim 23 wherein the first formulation does not contain polyols having a molecular weight of less than 950 in a molar ratio between polyol and active compound of formula I above 5, with the exception of lactose.
27. **(Previously presented)** A composition according to claim 23 wherein the first formulation does not contain polyols having a molecular weight of less than 950, with the exception of lactose.
28. **(Previously presented)** A composition according to claim 23 wherein the formulations are prepared in the form of powders, granules, solutions or suspensions.
29. **(Previously Presented)** A composition according to claim 23 wherein a polyol in the second formulation is mannitol.
30. **(Previously presented)** A composition according to claim 23 wherein at least one of the formulations further contains an alkalinizing agent.
31. **(Previously presented)** A composition according to claim 30 wherein the alkalinizing agent is sodium citrate.
32. **(Previously presented)** A composition according to claim 23 wherein the first formulation further contains one or more excipients selected from cyclodextrins, colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, flavors or colorants.

33. **(Previously presented)** A composition according to claim 23 wherein the first formulation further contains non-polyol sweetening agents such as acesulfame K, aspartame, saccharine, saccharine sodium or cyclamate.
34. **(Previously presented)** A composition according to claim 23 wherein the active compound in the first formulation is cetirizine dihydrochloride, levocetirizine dihydrochloride or efletirizine dihydrochloride.
35. **(Previously presented)** A composition according to claim 12 wherein the first formulation further contains a cyclodextrin.
36. **(Previously presented)** A composition according to claim 35 wherein the cyclodextrin is beta cyclodextrin.
37. **(Previously presented)** A composition according to claim 32 wherein the first formulation further contains a cyclodextrin.
38. **(Previously presented)** A composition according to claim 37 wherein the cyclodextrin is beta cyclodextrin.